AroCell AB was founded in 2003. The company is located in Uppsala, Sweden and develops and commercializes tests that can be used in the prognosis, monitoring and follow-up of cancer.
Oncologists need to monitor tumor growth during cancer treatment. AroCell has developed a test, the TK 210 ELISA for measuring the enzyme TK1, which is a protein that is elevated in the blood when there is increased cell turnover (cell growth and cell death) within the patient. A malignant tumor has high cell turnover and TK1 leaks out into the blood. A test for measuring TK1 therefore has a great potential clinical value.
The AroCell share (AROC) is listed on Nasdaq First North.